TG THERAPEUTICS, INC.
TGTX · XNASCIK 1001316fmd_0RP23JQYH9Q0FRVS2MVAFEEQNSManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2001 to Sep 30, 2026, 75 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 0 | 0 | 0 | 0 | 0 | 7 | 3 | 234 | 329 | 616 |
| Cost of revenue | – | – | – | – | – | 1 | 0 | 14 | 38 | 101 |
| Gross profit | – | – | – | – | – | 6 | 3 | 220 | 291 | 516 |
| Research and development | 69 | 103 | 159 | 154 | 166 | 223 | 125 | 76 | 94 | 160 |
| Selling, general and administrative | – | – | – | 15 | 108 | 128 | 95 | 123 | 154 | 232 |
| Total operating expenses | 79 | 119 | 175 | 169 | 274 | 351 | 196 | – | – | – |
| Operating income | (79) | (119) | (174) | (169) | (274) | (345) | (218) | 21 | 42 | 123 |
| Interest expense | – | 1 | 1 | 5 | 6 | 6 | 10 | 13 | 24 | 27 |
| Other non-operating income (expense) | 1 | 0 | 1 | (4) | (6) | (3) | (5) | (8) | (16) | (16) |
| Income before taxes | (78) | (0) | (0) | (0) | (0) | (348) | (224) | 13 | 26 | 107 |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | (340) |
| Net income from continuing operations | (78) | (0) | (0) | (0) | (0) | (348) | (224) | 13 | 23 | 447 |
| Net income | (78) | (118) | (173) | (173) | (279) | (348) | (224) | 13 | 23 | 447 |